# A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

> **NCT05819112** · — · TERMINATED · sponsor: **Sanofi** · enrollment: 14799 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05819112
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-25
- **Primary completion:** 2023-12-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 14799 (ACTUAL)
- **Why stopped:** Sponsor's decision. Termination decision unrelated to safety profile.
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05819112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05819112, "A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05819112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*